Acadia Pharmaceuticals’ CEO on Rebranding and Using AI
Acadia Pharmaceuticals CEO Catherine Owen Adams discusses the company's recent rebrand, expansion into rare disease marketing, and the use of AI.
Neurological biotech Acadia Pharmaceuticals has rolled out a rebrand as it expands into the rare disease space, with AI playing a major role in its marketing strategy.
- Rebranding to expand into rare disease space
- Using AI in marketing strategy
- Commercialization and marketing efforts
MM+M spoke with Acadia CEO Catherine Owen Adams on the company's recent rebrand, its expansion into rare disease and how it's using AI.
Adams discusses the benefits and challenges of marketing as a smaller biotech and how her marketing background is helping to steer the company into 2026.
Author's summary: Acadia Pharmaceuticals rebrands and expands into rare disease marketing with AI.
More News
- AFM and Marche du Film teaming on innovation forum and AI sessions
- Interdisciplinary Course Connects Biology, Astronomy, Physics and Filmmaking at Kennedy Mountain Campus | University of Denver
- REM line to Montreal's North Shore to begin Nov. 17, adding 14 new stations
- Gantry Arranges $9.3M Loan for Refinancing of Houston Apartment Building
- Internet services cut for hours by Amazon cloud outage
- Watch 'Conclave' thriller at De Valence!
- Colman Domingo Is the Cowardly Lion in 'Wicked: For Good'
- The lion of Zion has awakened - Israel Today
- Husband mourns influencer Stacey Hatfield, who passed after birth of son Axel
- Watch the NBA on ABC: See the 2025-2026 Season Schedule | ABC Updates